Histiocytosis in Injecting Drug Users

Enrolling by invitationOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Histiocytosis
Interventions
DIAGNOSTIC_TEST

Chitotriosidase

The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase

DIAGNOSTIC_TEST

Mass spectrometry

to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

DIAGNOSTIC_TEST

scanning electron microscope with energy-dispersive X-ray spectroscopy

to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

DIAGNOSTIC_TEST

Fluorescence microscopy

to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls

DIAGNOSTIC_TEST

Transcriptomics

To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples

Trial Locations (1)

33101

Tampere University Hospital, Tampere

All Listed Sponsors
collaborator

Tampere University

OTHER

collaborator

University of Oulu

OTHER

collaborator

University of Turku

OTHER

collaborator

University of Helsinki

OTHER

lead

Tampere University Hospital

OTHER